Structural heart disease as the cause of syncope

Autor: R.B. Guimarães, V. Essebag, M. Furlanetto, J.P.G. Yanez, M.G. Farina, D. Garcia, E.D. Almeida, L. Stephan, G.G. Lima, T.L.L. Leiria

Publikováno v: Brazilian Journal of Medical and Biological Research, Vol 51, Iss 4 (2018)

We described the clinical evolution of patients with structural heart disease presenting at the emergency room with syncope. Patients were stratified according to their syncope etiology and available scores for syncope prognostication. Cox proportion

Externí odkaz: https://doaj.org/article/bbc8cfbe726645ec87784c17726a29e8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators

Autor: Wojciech Zareba, James P. Daubert, Christopher A. Beck, David T. Huang, Jeffrey D. Alexis, Mary W. Brown, Kathryn Pyykkonen, Scott McNitt, David Oakes, Changyong Feng, Mehmet K. Aktas, Felix Ayala-Parades, Adrian Baranchuk, Marc Dubuc, Mark Haigney, Alexander Mazur, Craig A. McPherson, L. Brent Mitchell, Andrea Natale, Jonathan P. Piccini, Merritt Raitt, Mayer Y. Rashtian, Claudio Schuger, Stephen Winters, Seth J. Worley, Ohad Ziv, Arthur J. Moss, W. Zareba, K. Pyykkonen, A. Buttaccio, E. Perkins, D. DeGrey, S. Robertson, A.J. Moss, M. Brown, R. Lansing, A. Oberer, B. Polonsky, V. Ross, A. Papernov, S. Schleede, C. Beck, D. Oakes, C. Feng, S. McNitt S, W.J. Hall, A. Moss, J. Daubert, D. Huang, S. Winters, C. Schuger, M. Haigney, J. Piccini, J. Alexis, L. Chen, A. Miller, J.F. Richeson, S. Rosero, V. Kutyifa, A. Shah, G. Lamas, F. Cohn, F. Harrell, I. Piña, J. Poole, M. Sullivan, D. Lathrop, N. Geller, R. Boineau, J. Trondell, L. Cooper, E. Itturiaga, C. Gottlieb, S. Greer, C. Perzanowski, C. McPherson, C. Hedgepeth, C. Assal, T. Salam, I. Woollett, G. Tomassoni, F. Ayala-Paredes, A. Russo, S. Punnam, R. Sangrigoli, S. Sloan, S. Kutalek, A. Sun, D. Lustgarten, G. Monir, D. Haithcock, R. Sorrentino, D. Cannom, J. Kluger, S. Varanasi, M. Rashtian, F. Philippon, R. Berger, M. Mazzella, T. Lessmeier, J. Silver, S. Worley, M. Bernabei, D. Esberg, M. Dixon, P. LeLorier, Y. Greenberg, V. Essebag, G. Venkataraman, T. Shinn, M. Dubuc, G. Turitto, C. Henrikson, M. Mirro, M. Raitt, A. Baranchuk, G. O'Neill, E. Lockwood, M. Vloka, J. Hurwitz, R.H. Mead, P. Somasundarum, E. Aziz, E. Rashba, A. Budzikowski, M. Cox, A. Natale, E. Chung, O. Ziv, F. McGrew, K. Tamirisa, A. Greenspon, M. Estes, S. Taylor, R. Janardhanan, L.B. Mitchell, M. Burke, M. Attari, B. Mikaelian, S. Hsu, J. Conti, A. Mazur, S. Shorofsky, L. Rosenthal, S. Sakaguchi, D. Wolfe, G. Flaker, S. Saba, M. Aktas, P. Mason, A. Shalaby, D. Musat, R. Abraham, K. Ellenbogen, C. Fellows, N. Kavesh, G. Thomas, D. Hemsworth, B. Williamson

Publikováno v: Journal of the American College of Cardiology. 72:636-645

Background Ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a challenging problem in patients with implantable cardioverter-defibrillators (ICDs). Objectives This study aimed to determine whether ranolazine administration decreas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a3da108e14703d249a00ad70af08bb8
https://doi.org/10.1016/j.jacc.2018.04.086